MindMaze Therapeutics Holding S.A.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTY) is a Swiss commercial-stage biopharmaceutical company that develops and commercializes novel patent-protected therapies for specialty rare and ultra-rare diseases with unmet medical needs, particularly in rare dermatological metabolic and respiratory conditions; its core pipeline includes RLF-TD011 a proprietary acid-oxidizing hypochlorous acid topical spray for epidermolysis bullosa RLF-OD032 a next-generation highly concentrated liquid formulation of sapropterin dihydrochloride for phenylketonuria and earlier-stage candidates such as RLF-100 a synthetic vasoactive intestinal peptide for acute respiratory distress syndrome and chronic lung diseases; the company also generates revenue from out-licensed commercial products including OLPRUVA (sodium phenylbutyrate) for urea cycle disorders GOLIKE (sapropterin) for phenylketonuria CAMBIA for acute migraine and legacy offerings like SETOFILM/ONDISSOLVE films for nausea and vomiting associated with chemotherapy radiotherapy and postoperative effects leveraging proprietary drug delivery platforms such as Physiomimic and TEHCLO. Founded in 2013 and headquartered at Avenue de Sécheron 15 in Geneva Switzerland Relief operates globally across Switzerland Europe North America and other regions through partnerships and licensing agreements targeting patients with chronic debilitating disorders. Recent developments include the August 2024 royalty sales agreement with SWK Funding providing up to $11 million in non-dilutive funding with $5.75 million upfront and additional milestones achieved such as a $2 million payment in September 2024 to advance RLF-TD011 and pipeline efforts; positive pivotal bioequivalence study results for RLF-OD032 in October 2025 supporting planned U.S. regulatory submission FDA Rare Pediatric Disease Designation and QIDP response for RLF-TD011 in May and June 2025 respectively alongside European Patent Office grants for RLF-TD011; strategic sale of GOLIKE rights ex-U.S. in January 2025 to complete transition while retaining global supply obligations; termination of merger discussions with Renexxion in March 2025 followed by a proposed business combination with NeuroX (successor to MindMaze) announced in July 2025 with definitive agreement in October 2025 shareholder approval in November 2025 and joint presentation in November 2025 valuing the combined entity to focus on AI-driven health technologies while advancing rare disease assets; and filing of Form 15F in December 2024 to end SEC reporting with cash runway into late 2026 per the 2024 annual report and 2025 half-year results.
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Relief Therapeutics Announces Results of Annual General Meeting
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update